• 1  Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg 1982;69(3):412–22. Cross Ref link Pubmed link
  • 2  Wassef M, Blei F, Adams D, et al. The 2014 updated ISSVA* classification of vascular anomalies. Pediatrics (submitted).
  • 3  Jacobs AH, Walton RG. The incidence of birthmarks in the neonate. Pediatrics 1976;58(2):218–22. Pubmed link
  • 4  Boon LM, Vikkula M. Vascular anomalies. In: Wolff K, Goldsmith LA, Katz SI, Gilchrest BA, Paller AS, Leffell D, eds. Fitzpatrick's Dermatology in General Medicine, Vol. 2, 8th edn. New York: McGraw‐Hill, 2012:2076–94.
  • 5  Shirley MD, Tang H, Gallione CJ, et al. Sturge‐Weber syndrome and port‐wine stains caused by somatic mutation in GNAQ. New Engl J Med 2013;368(21):1971–9. Cross Ref link Pubmed link
  • 6  Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. Nature 2009;457(7229):599–602. Cross Ref link Pubmed link
  • 7  Garden JM, Bakus AD. Clinical efficacy of the pulsed dye laser in the treatment of vascular lesions. J Dermatol Surg Oncol 1993;19(4):321–6. Cross Ref link Pubmed link
  • 8  Sujansky E, Conradi S. Outcome of Sturge‐Weber syndrome in 52 adults. Am J Med Genet 1995;57(1):35–45. Cross Ref link Pubmed link
  • 9  Eerola I, Boon LM, Mulliken JB, et al. Capillary malformation‐arteriovenous malformation, a new clinical and genetic disorder caused by RASA1 mutations. Am J Hum Genet 2003;73(6):1240–9. Cross Ref link Pubmed link
  • 10  Revencu N, Boon LM, Mendola A, et al. RASA1 mutations and associated phenotypes in 68 families with capillary malformation‐arteriovenous malformation. Hum Mutat 2013;34(12):1632–41. Cross Ref link Pubmed link
  • 11  Eerola I, Boon L, Watanabe S, Grynberg H, Mulliken J, Vikkula M. Familial capillary malformation maps to chromosome 5q. Eur J Hum Genet 2002;10(6):216. Cross Ref link
  • 12  Boon LM, Mulliken JB, Vikkula M. RASA1: variable phenotype with capillary and arteriovenous malformations. Curr Opin Genet Dev 2005;15(3):265–9. Cross Ref link Pubmed link
  • 13  Anand S, Majeti BK, Acevedo LM, et al. MicroRNA‐132‐mediated loss of p120RasGAP activates the endothelium to facilitate pathological angiogenesis. Nat Med 2010;16(8):909–14. Cross Ref link Pubmed link
  • 14  Revencu N, Boon LM, Mulliken JB, et al. Parkes Weber syndrome, vein of Galen aneurysmal malformation, and other fast‐flow vascular anomalies are caused by RASA1 mutations. Hum Mutat 2008;29(7):959–65. Cross Ref link Pubmed link
  • 15  Kawasaki J, Aegerter S, Fevurly RD, et al. RASA1 functions in EPHB4 signaling pathway to suppress endothelial mTORC1 activity. J Clin Invest 2014;124(6):2774–84. Cross Ref link Pubmed link
  • 16  Boon LM, Revencu N, Vikkula M. Capillary malformation–arteriovenous malformation and RASA1 mutations. 2011. http://www.els.net/WileyCDA/ElsArticle/refId‐a0022479.html (last accessed January 2015).
  • 17  Enjolras O, Chapot R, Merland JJ. Vascular anomalies and the growth of limbs: a review. J Pediatr Orthop B 2004;13(6):349–57. Cross Ref link Pubmed link
  • 18  Frain‐Bell W. Angioma serpiginosum. Br J Dermatol 1957;69(7/8):251–68. Cross Ref link Pubmed link
  • 19  Blinkenberg EO, Brendehaug A, Sandvik AK, Vatne O, Hennekam RC, Houge G. Angioma serpiginosum with oesophageal papillomatosis is an X‐linked dominant condition that maps to Xp11.3‐Xq12. Eur J Hum Genet 2007;15(5):543–7. Cross Ref link Pubmed link
  • 20  Houge G, Oeffner F, Grzeschik KH. An Xp11.23 deletion containing PORCN may also cause angioma serpiginosum, a cosmetic skin disease associated with extreme skewing of X‐inactivation. Eur J Hum Genet 2008;16(9):1027–8. Cross Ref link Pubmed link
  • 21  Denier C, Labauge P, Bergametti F, et al. Genotype–phenotype correlations in cerebral cavernous malformations patients. Ann Neurol 2006;60(5):550–6. Cross Ref link Pubmed link
  • 22  Stahl S, Gaetzner S, Voss K, et al. Novel CCM1, CCM2, and CCM3 mutations in patients with cerebral cavernous malformations: in‐frame deletion in CCM2 prevents formation of a CCM1/CCM2/CCM3 protein complex. Hum Mutat 2008;29(5):709–17. Cross Ref link Pubmed link
  • 23  Akers AL, Johnson E, Steinberg GK, Zabramski JM, Marchuk DA. Biallelic somatic and germline mutations in cerebral cavernous malformations (CCMs): evidence for a two‐hit mechanism of CCM pathogenesis. Hum Mol Genet 2009;18(5):919–30. Pubmed link
  • 24  Pagenstecher A, Stahl S, Sure U, Felbor U. A two‐hit mechanism causes cerebral cavernous malformations: complete inactivation of CCM1, CCM2 or CCM3 in affected endothelial cells. Hum Mol Genet 2009;18(5):911–18. Pubmed link
  • 25  Sirvente J, Enjolras O, Wassef M, Tournier‐Lasserve E, Labauge P. Frequency and phenotypes of cutaneous vascular malformations in a consecutive series of 417 patients with familial cerebral cavernous malformations. J Eur Acad Dermatol Venereol 2009;23(9):1066–72. Cross Ref link Pubmed link
  • 26  Labauge P, Denier C, Bergametti F, Tournier‐Lasserve E. Genetics of cavernous angiomas. Lancet Neurol 2007;6(3):237–44. Cross Ref link Pubmed link
  • 27  Happle R. Lethal genes surviving by mosaicism: a possible explanation for sporadic birth defects involving the skin. J Am Acad Dermatol 1987;16(4):899–906. Cross Ref link Pubmed link
  • 28  Kurek KC, Luks VL, Ayturk UM, et al. Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am J Hum Genet 2012;90(6):1108–15. Cross Ref link Pubmed link
  • 29  Riviere JB, Mirzaa GM, O'Roak BJ, et al. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat Genet 2012;44(8):934–40. Cross Ref link Pubmed link
  • 30  Lindhurst MJ, Sapp JC, Teer JK, et al. A mosaic activating mutation in AKT1 associated with the Proteus syndrome. New Engl J Med 2011;365(7):611–19. Cross Ref link Pubmed link
  • 31  Jacob AG, Driscoll DJ, Shaughnessy WJ, Stanson AW, Clay RP, Gloviczki P. Klippel‐Trenaunay syndrome: spectrum and management. Mayo Clin Proc 1998;73(1):28–36. Cross Ref link Pubmed link
  • 32  Klippel M, Trénaunay P. Du naevus variquex osteohypertrophique. Arch Gen Med 1900;3:641–72.
  • 33  Sapp JC, Turner JT, van de Kamp JM, van Dijk FS, Lowry RB, Biesecker LG. Newly delineated syndrome of congenital lipomatous overgrowth, vascular malformations, and epidermal nevi (CLOVE syndrome) in seven patients. Am J Med Genet A 2007;143A(24):2944–58. Cross Ref link Pubmed link
  • 34  Biesecker L. The challenges of Proteus syndrome: diagnosis and management. Eur J Hum Genet 2006;14(11):1151–7. Cross Ref link Pubmed link
  • 35  Keppler‐Noreuil KM, Sapp JC, Lindhurst MJ, et al. Clinical delineation and natural history of the PIK3CA‐related overgrowth spectrum. Am J Med Genet A 2014;164(7):1713–33. Cross Ref link
  • 36  Cohen MM, Jr. Proteus syndrome: an update. Am J Med Genet C Semin Med Genet 2005;137C(1):38–52. Cross Ref link Pubmed link
  • 37  Turner JT, Cohen MM, Jr, Biesecker LG. Reassessment of the Proteus syndrome literature: application of diagnostic criteria to published cases. Am J Med Genet A 2004;130A(2):111–22. Cross Ref link Pubmed link
  • 38  Clayton‐Smith J, Kerr B, Brunner H, et al. Macrocephaly with cutis marmorata, haemangioma and syndactyly – a distinctive overgrowth syndrome. Clin Dysmorphol 1997;6(4):291–302. Cross Ref link Pubmed link
  • 39  Moore CA, Toriello HV, Abuelo DN, et al. Macrocephaly‐cutis marmorata telangiectatica congenita: a distinct disorder with developmental delay and connective tissue abnormalities. Am J Med Genet 1997;70(1):67–73. Cross Ref link Pubmed link
  • 40  Franceschini P, Licata D, Di Cara G, Guala A, Franceschini D, Genitori L. Macrocephaly‐cutis marmorata telangiectatica congenita without cutis marmorata? Am J Med Genet 2000;90(4):265–9. Cross Ref link Pubmed link
  • 41  Robertson SP, Gattas M, Rogers M, Ades LC. Macrocephaly–cutis marmorata telangiectatica congenita: report of five patients and a review of the literature. Clin Dysmorphol 2000;9(1):1–9. Cross Ref link Pubmed link
  • 42  Conway RL, Pressman BD, Dobyns WB, et al. Neuroimaging findings in macrocephaly‐capillary malformation: a longitudinal study of 17 patients. Am J Med Genet A 2007;143A(24):2981–3008. Cross Ref link Pubmed link
  • 43  Toriello HV, Mulliken JB. Accurately renaming macrocephaly‐cutis marmorata telangiectatica congenita (M‐CMTC) as macrocephaly‐capillary malformation (M‐CM). Am J Med Genet A 2007;143A(24):3009. Cross Ref link Pubmed link
  • 44  Mirzaa GM, Conway RL, Gripp KW, et al. Megalencephaly‐capillary malformation (MCAP) and megalencephaly‐polydactyly‐polymicrogyria‐hydrocephalus (MPPH) syndromes: two closely related disorders of brain overgrowth and abnormal brain and body morphogenesis. Am J Med Genet A 2012;158A(2):269–91. Cross Ref link Pubmed link
  • 45  Gloviczki P, Driscoll DJ. Klippel‐Trenaunay syndrome: current management. Phlebol Venous Forum R Soc Med 2007;22(6):291–8. Cross Ref link
  • 46  Oduber CE, Gerdes VE, van der Horst CM, Bresser P. Vascular malformations as underlying cause of chronic thromboembolism and pulmonary hypertension. J Plast Reconstr Aesthet Surg 2009;62(5):684–9; discussion 689. Cross Ref link Pubmed link
  • 47  Carter MT, Boycott KM. Microcephaly‐capillary malformation syndrome: a story of rapid emergence of a new recognizable entity. Am J Med Genet A 2011;155A(9):2078–9. Cross Ref link Pubmed link
  • 48  Mirzaa GM, Paciorkowski AR, Smyser CD, Willing MC, Lind AC, Dobyns WB. The microcephaly‐capillary malformation syndrome. Am J Med Genet A 2011;155A(9):2080–7. Cross Ref link Pubmed link
  • 49  McDonell LM, Mirzaa GM, Alcantara D, et al. Mutations in STAMBP, encoding a deubiquitinating enzyme, cause microcephaly‐capillary malformation syndrome. Nat Genet 2013;45(5):556–62. Cross Ref link Pubmed link
  • 50  Fleetwood IG, Steinberg GK. Arteriovenous malformations. Lancet 2002;359(9309):863–73. Cross Ref link Pubmed link
  • 51  Choi JH, Mohr JP. Brain arteriovenous malformations in adults. Lancet Neurol 2005;4(5):299–308. Cross Ref link Pubmed link
  • 52  Paltiel HJ, Burrows PE, Kozakewich HP, Zurakowski D, Mulliken JB. Soft‐tissue vascular anomalies: utility of US for diagnosis. Radiology 2000;214(3):747–54. Cross Ref link Pubmed link
  • 53  Lebrin F, Srun S, Raymond K, et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010;16(4):420–8. Cross Ref link Pubmed link
  • 54  Boon LM, Qin V, Marot L, et al. Thalidomide is an efficient treatment for arteriovenous malformations responsible for pain, ulceration and/or bleeding. in preparation.
  • 55  Braverman IM, Keh A, Jacobson BS. Ultrastructure and three‐dimensional organization of the telangiectases of hereditary hemorrhagic telangiectasia. J Invest Dermatol 1990;95(4):422–7. Cross Ref link Pubmed link
  • 56  Bourdeau A, Cymerman U, Paquet ME, et al. Endoglin expression is reduced in normal vessels but still detectable in arteriovenous malformations of patients with hereditary hemorrhagic telangiectasia type 1. Am J Pathol 2000;156(3):911–23. Cross Ref link Pubmed link
  • 57  Krings T, Ozanne A, Chng SM, Alvarez H, Rodesch G, Lasjaunias PL. Neurovascular phenotypes in hereditary haemorrhagic telangiectasia patients according to age. Review of 50 consecutive patients aged 1 day–60 years. Neuroradiology 2005;47(10):711–20. Cross Ref link Pubmed link
  • 58  McAllister KA, Grogg KM, Johnson DW, et al. Endoglin, a TGF‐beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8(4):345–51. Cross Ref link Pubmed link
  • 59  Johnson DW, Berg JN, Baldwin MA, et al. Mutations in the activin receptor‐like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13(2):189–95. Cross Ref link Pubmed link
  • 60  Gallione CJ, Repetto GM, Legius E, et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004;363(9412):852–9. Cross Ref link Pubmed link
  • 61  Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005;42(7):577–82. Cross Ref link Pubmed link
  • 62  Bayrak‐Toydemir P, McDonald J, Akarsu N, et al. A fourth locus for hereditary hemorrhagic telangiectasia maps to chromosome 7. Am J Med Genet A 2006;140(20):2155–62. Cross Ref link Pubmed link
  • 63  Wooderchak‐Donahue WL, McDonald J, O'Fallon B, et al. BMP9 mutations cause a vascular‐anomaly syndrome with phenotypic overlap with hereditary hemorrhagic telangiectasia. Am J Hum Genet 2013;93(3):530–7. Cross Ref link Pubmed link
  • 64  Govani FS, Shovlin CL. Hereditary haemorrhagic telangiectasia: a clinical and scientific review. Eur J Hum Genet 2009;17(7):860–71. Cross Ref link Pubmed link
  • 65  Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010;24(6):203–19. Cross Ref link Pubmed link
  • 66  Easey AJ, Wallace GM, Hughes JM, Jackson JE, Taylor WJ, Shovlin CL. Should asymptomatic patients with hereditary haemorrhagic telangiectasia (HHT) be screened for cerebral vascular malformations? Data from 22,061 years of HHT patient life. J Neurol Neurosurg Psychiatry 2003;74(6):743–8. Cross Ref link Pubmed link
  • 67  Faughnan ME, Palda VA, Garcia‐Tsao G, et al. International guidelines for the diagnosis and management of hereditary haemorrhagic telangiectasia. J Med Genet 2011;48(2):73–87. Cross Ref link Pubmed link
  • 68  Dupuis‐Girod S, Ginon I, Saurin JC, et al. Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output. JAMA 2012;307(9):948–55. Pubmed link
  • 69  Pilarski R, Stephens JA, Noss R, Fisher JL, Prior TW. Predicting PTEN mutations: an evaluation of Cowden syndrome and Bannayan‐Riley‐Ruvalcaba syndrome clinical features. J Med Genet 2011;48(8):505–12. Cross Ref link Pubmed link
  • 70  Nelen MR, Kremer H, Konings IB, et al. Novel PTEN mutations in patients with Cowden disease: absence of clear genotype–phenotype correlations. Eur J Hum Genet 1999;7(3):267–73. Cross Ref link Pubmed link
  • 71  Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer 2007;7(1):35–45. Cross Ref link Pubmed link
  • 72  Marsh DJ, Coulon V, Lunetta KL, et al. Mutation spectrum and genotype‐phenotype analyses in Cowden disease and Bannayan‐Zonana syndrome, two hamartoma syndromes with germline PTEN mutation. Hum Mol Genet 1998;7(3):507–15. Cross Ref link Pubmed link
  • 73  Marsh DJ, Kum JB, Lunetta KL, et al. PTEN mutation spectrum and genotype‐phenotype correlations in Bannayan‐Riley‐Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999;8(8):1461–72. Cross Ref link Pubmed link
  • 74  Longy M, Coulon V, Duboue B, et al. Mutations of PTEN in patients with Bannayan‐Riley‐Ruvalcaba phenotype. J Med Genet 1998;35(11):886–9. Cross Ref link Pubmed link
  • 75  Tan WH, Baris HN, Burrows PE, et al. The spectrum of vascular anomalies in patients with PTEN mutations: implications for diagnosis and management. J Med Genet 2007;44(9):594–602. Cross Ref link Pubmed link
  • 76  Gorlin RJ, Cohen MM, Jr, Condon LM, Burke BA. Bannayan‐Riley‐Ruvalcaba syndrome. Am J Med Genet 1992;44(3):307–14. Cross Ref link Pubmed link
  • 77  Parisi MA, Dinulos MB, Leppig KA, Sybert VP, Eng C, Hudgins L. The spectrum and evolution of phenotypic findings in PTEN mutation positive cases of Bannayan‐Riley‐Ruvalcaba syndrome. J Med Genet 2001;38(1):52–8. Cross Ref link Pubmed link
  • 78  Stanich PP, Pilarski R, Rock J, Frankel WL, El‐Dika S, Meyer MM. Colonic manifestations of PTEN hamartoma tumor syndrome: case series and systematic review. World J Gastroenterol 2014;20(7):1833–8. Cross Ref link Pubmed link
  • 79  Iacobas I, Burrows PE, Adams DM, Sutton VR, Hollier LH, Chintagumpala MM. Oral rapamycin in the treatment of patients with hamartoma syndromes and PTEN mutation. Pediatr Blood Cancer 2011;57(2):321–3. Cross Ref link Pubmed link
  • 80  Dompmartin A, Vikkula M, Boon LM. Venous malformation: update on aetiopathogenesis, diagnosis and management. Phlebology 2010;25:224–35. Cross Ref link Pubmed link
  • 81  Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet 2007;16(Spec No. 2):R140–9. Cross Ref link Pubmed link
  • 82  Dompmartin A, Ballieux F, Thibon P, et al. Elevated D‐dimer level in the differential diagnosis of venous malformations. Arch Dermatol 2009;145(11):1239–44. Pubmed link
  • 83  Limaye N, Boon LM, Vikkula M. From germline towards somatic mutations in the pathophysiology of vascular anomalies. Hum Mol Genet 2009;18(R1):R65–74. Cross Ref link Pubmed link
  • 84  Dompmartin A, Acher A, Thibon P, et al. Association of localized intravascular coagulopathy with venous malformations. Arch Dermatol 2008;144(7):873–7. Cross Ref link Pubmed link
  • 85  Mazoyer E, Enjolras O, Bisdorff A, Perdu J, Wassef M, Drouet L. Coagulation disorders in patients with venous malformation of the limbs and trunk: a case series of 118 patients. Arch Dermatol 2008;144(7):861–7. Cross Ref link Pubmed link
  • 86  Vikkula M, Boon LM, Carraway KL, 3rd, et al. Vascular dysmorphogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2. Cell 1996;87(7):1181–90. Cross Ref link Pubmed link
  • 87  Limaye N, Wouters V, Uebelhoer M, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet 2009;41(1):118–24. Cross Ref link Pubmed link
  • 88  Soblet J, Limaye N, Uebelhoer M, Boon LM, Vikkula M. Variable somatic mutations in half of sporadic venous malformations. Mol Syndromol 2013;4(4):179–83. Pubmed link
  • 89  Soblet J, Limaye N, Cordisco M, et al. Identification of the cause of blue rubber bleb nevus syndrome. J Clin Invest (submitted).
  • 90  Uebelhoer M, Natynki M, Kangas J, et al. Venous malformation‐causative TIE2 mutations mediate an AKT‐dependent decrease in PDGFB. Hum Mol Genet 2013;22(17):3438–48. Cross Ref link Pubmed link
  • 91  Boon LM, Mulliken JB, Enjolras O, Vikkula M. Glomuvenous malformation (glomangioma) and venous malformation: distinct clinicopathologic and genetic entities. Arch Dermatol 2004;140(8):971–6. Cross Ref link Pubmed link
  • 92  Berenguer B, Burrows PE, Zurakowski D, Mulliken JB. Sclerotherapy of craniofacial venous malformations: complications and results. Plast Reconstr Surg 1999;104(1):1–11; discussion 12–15. Cross Ref link Pubmed link
  • 93  Rodriguez‐Manero M, Aguado L, Redondo P. Pulmonary arterial hypertension in patients with slow‐flow vascular malformations. Arch Dermatol 2010;146(12):1347–52. Cross Ref link Pubmed link
  • 94  Boon LM, Vanwijck R. [Medical and surgical treatment of venous malformations.] Ann Chir Plast Esthet 2006;51(4/5):403–11. Cross Ref link Pubmed link
  • 95  Hammer FD, Boon LM, Mathurin P, Vanwijck RR. Ethanol sclerotherapy of venous malformations: evaluation of systemic ethanol contamination. J Vasc Interv Radiol 2001;12(5):595–600. Cross Ref link Pubmed link
  • 96  Dompmartin A, Blaizot X, Théron J, et al. Radio‐opaque ethylcellulose‐ethanol is a safe and efficient sclerosing agent for venous malformations. Eur Radiol. 2011;21(12):2647–56. Cross Ref link Pubmed link
  • 97  Boscolo E, Kang K‐T, Limaye N, et al. Venous malformation : from causative mutations to murine model and targeted therapy. J Clin Invest (submitted).
  • 98  Boon LM, Mulliken JB, Vikkula M, et al. Assignment of a locus for dominantly inherited venous malformations to chromosome 9p. Hum Mol Genet 1994;3(9):1583–7. Cross Ref link Pubmed link
  • 99  Wouters V, Limaye N, Uebelhoer M, et al. Hereditary cutaneomucosal venous malformations are caused by TIE2 mutations with widely variable hyper‐phosphorylating effects. Eur J Hum Genet 2010;18(4):414–20. Cross Ref link Pubmed link
  • 100  Boon LM, Ballieux F, Vikkula M. Pathogenesis of vascular anomalies. Clin Plast Surg 2011;38(1):7–19. Cross Ref link Pubmed link
  • 101  Gascoyen GG. Case of nevus involving the parotid gland and causing death from suffocation: nevi of the viscera. Trans Patholog Soc Lond 1860;11:article 267.
  • 102  Bean WB. Vascular Spiders and Related Lesions of the Skin. Springfield, IL: Charles C. Thomas; Oxford: Blackwell Scientific Publications, 1958.
  • 103  Oranje AP. Blue rubber bleb nevus syndrome. Pediatr Dermatol 1986;3(4):304–10. Cross Ref link Pubmed link
  • 104  Fishman SJ, Smithers CJ, Folkman J, et al. Blue rubber bleb nevus syndrome: surgical eradication of gastrointestinal bleeding. Ann Surg 2005;241(3):523–8. Cross Ref link Pubmed link
  • 105  Fishman SJ, Fox VL. Visceral vascular anomalies. Gastrointest Endo Clin North Am 2001;11(4):813–34,viii.
  • 106  Yuksekkaya H, Ozbek O, Keser M, Toy H. Blue rubber bleb nevus syndrome: successful treatment with sirolimus. Pediatrics 2012;129(4):e1080–4. Cross Ref link Pubmed link
  • 107  Irrthum A, Brouillard P, Enjolras O, et al. Linkage disequilibrium narrows locus for venous malformation with glomus cells (VMGLOM) to a single 1.48 Mbp YAC. Eur J Hum Genet 2001;9(1):34–8. Cross Ref link Pubmed link
  • 108  Brouillard P, Boon LM, Mulliken JB, et al. Mutations in a novel factor, glomulin, are responsible for glomuvenous malformations (“glomangiomas”). Am J Hum Genet 2002;70(4):866–74. Cross Ref link Pubmed link
  • 109  Brouillard P, Ghassibe M, Penington A, et al. Four common glomulin mutations cause two thirds of glomuvenous malformations (“familial glomangiomas”): evidence for a founder effect. J Med Genet 2005;42(2):e13. Cross Ref link Pubmed link
  • 110  Amyere M, Aerts V, Brouillard P, et al. Somatic uniparental isodisomy explains multifocality of glomuvenous malformations. Am J Hum Genet 2013;92(2):188–96. Cross Ref link Pubmed link
  • 111  Boon LM, Brouillard P, Irrthum A, et al. A gene for inherited cutaneous venous anomalies (“glomangiomas”) localizes to chromosome 1p21‐22. Am J Hum Genet 1999;65(1):125–33. Cross Ref link Pubmed link
  • 112  Brouillard P, Boon LM, Revencu N, et al. Genotypes and phenotypes of 162 families with a glomulin mutation. Mol Syndromol 2013;4(4):157–64. Pubmed link
  • 113  Mallory SB, Enjolras O, Boon LM, et al. Congenital plaque‐type glomuvenous malformations presenting in childhood. Arch Dermatol 2006;142(7):892–6. Cross Ref link Pubmed link
  • 114  Goujon E, Cordoro KM, Barat M, et al. Congenital plaque‐type glomuvenous malformations associated with fetal pleural effusion and ascites. Pediatr Dermatol 2010;28(5):528–31. Cross Ref link Pubmed link
  • 115  Maffucci A. Di un caso encondroma ed angioma multiplo. Contribuzione alla genesi embrionale dei tumori. In: Movimento Medico‐chirurgico, Vol. 3. Napoli, 1881:399–412, 565–75.
  • 116  Couvineau A, Wouters V, Bertrand G, et al. PTHR1 mutations associated with Ollier disease result in receptor loss of function. Hum Mol Genet 2008;17(18):2766–75. Cross Ref link Pubmed link
  • 117  Bowen ME, Boyden ED, Holm IA, et al. Loss‐of‐function mutations in PTPN11 cause metachondromatosis, but not Ollier disease or Maffucci syndrome. PLOS Genet 2011;7(4):e1002050. Cross Ref link Pubmed link
  • 118  Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondroma and spindle cell hemangioma in Ollier disease and Maffucci syndrome. Nat Genet 2011;43(12):1256–61. Cross Ref link Pubmed link
  • 119  Amary MF, Damato S, Halai D, et al. Ollier disease and Maffucci syndrome are caused by somatic mosaic mutations of IDH1 and IDH2. Nat Genet 2011;43(12):1262–5. Cross Ref link Pubmed link
  • 120  Amyere M, Dompmartin A, Wouters V, et al. Common somatic alterations identified in Maffucci syndrome by molecular karyotyping. Mol Syndromol 2014,5(6):259–67. Pubmed link
  • 121  Spranger J, Kemperdieck H, Bakowski H, Opitz JM. Two peculiar types of enchondromatosis. Pediatr Radiol 1978;7(4):215–19. Cross Ref link Pubmed link
  • 122  Bhargava R, Leonard NJ, Chan AK, Spranger J. Autosomal dominant inheritance of spondyloenchondrodysplasia. Am J Med Genet A 2005;135(3):282–8. Cross Ref link Pubmed link
  • 123  Pansuriya TC, Kroon HM, Bovee JV. Enchondromatosis: insights on the different subtypes. Int J Clin Exp Pathol 2010;3(6):557–69. Pubmed link
  • 124  Casal D, Mavioso C, Mendes MM, Mouzinho MM. Hand involvement in Ollier disease and Maffucci syndrome: a case series. Acta Reumatol Port 2010;35(3):375–8. Pubmed link
  • 125  Auyeung J, Mohanty K, Tayton K. Maffucci lymphangioma syndrome: an unusual variant of Ollier's disease, a case report and a review of the literature. J Pediatr Orthop B 2003;12(2):147–50. Pubmed link
  • 126  Schwartz HS, Zimmerman NB, Simon MA, Wroble RR, Millar EA, Bonfiglio M. The malignant potential of enchondromatosis. J Bone Joint Surg Am 1987;69(2):269–74. Pubmed link
  • 127  Albregts AE, Rapini RP. Malignancy in Maffucci's syndrome. Dermatol Clin 1995;13(1):73–8. Pubmed link
  • 128  Lewis RJ, Ketcham AS. Maffucci's syndrome: functional and neoplastic significance. Case report and review of the literature. J Bone Joint Surg Am 1973;55(7):1465–79. Pubmed link
  • 129  Kaplan RP, Wang JT, Amron DM, Kaplan L. Maffucci's syndrome: two case reports with a literature review. J Am Acad Dermatol 1993;29(5 Pt 2):894–9. Cross Ref link Pubmed link
  • 130  Mendola A, Schlögel M, Ghalamkarpour A, et al. Mutations in VEGFR3 signaling pathway explain 36% of familial lymphedema. Mol Syndromol 2013;4(6):257–66. Cross Ref link Pubmed link
  • 131  Brouillard P, Boon L, Vikkula M. Genetics of lymphatic anomalies. J Clin Invest 2014;124(3):898–904. Cross Ref link Pubmed link
  • 132  Galambos C, Nodit L. Identification of lymphatic endothelium in pediatric vascular tumors and malformations. Pediatr Dev Pathol 2005;8(2):181–9. Cross Ref link Pubmed link
  • 133  Alomari AI. Characterization of a distinct syndrome that associates complex truncal overgrowth, vascular, and acral anomalies: a descriptive study of 18 cases of CLOVES syndrome. Clin Dysmorphol 2009;18(1):1–7. Cross Ref link Pubmed link
  • 134  Ballieux F, Modarressi A, Hammer F, et al. Reconstructive surgery in the management of a patient with CLOVES syndrome. J Plast Reconstr Aesthet Surg 2013;66(12):1813–15. Cross Ref link Pubmed link
  • 135  Schlögel MJ, Mendola A, Fastré E, et al. No locus heterogeneity in familial microcephaly with or without chorioretinopathy, lymphedema, or mental retardation syndrome. submitted.
  • 136  Marler JJ, Fishman SJ, Upton J, et al. Prenatal diagnosis of vascular anomalies. J Pediatr Surg 2002;37(3):318–26. Cross Ref link Pubmed link
  • 137  Moller G, Priemel M, Amling M, Werner M, Kuhlmey AS, Delling G. The Gorham‐Stout syndrome (Gorham's massive osteolysis). A report of six cases with histopathological findings. J Bone Joint Surg Br 1999;81(3):501–6. Cross Ref link Pubmed link
  • 138  Lala S, Mulliken JB, Alomari AI, Fishman SJ, Kozakewich HP, Chaudry G. Gorham‐Stout disease and generalized lymphatic anomaly – clinical, radiologic, and histologic differentiation. Skeletal Radiol 2013;42(7):917–24. Cross Ref link Pubmed link
  • 139  Siegel MJ, Glazer HS, St Amour TE, Rosenthal DD. Lymphangiomas in children: MR imaging. Radiology 1989;170(2):467–70. Cross Ref link Pubmed link
  • 140  Borecky N, Gudinchet F, Laurini R, Duvoisin B, Hohlfeld J, Schnyder P. Imaging of cervico‐thoracic lymphangiomas in children. Pediatr Radiol 1995;25(2):127–30. Cross Ref link Pubmed link
  • 141  Burrows PE, Laor T, Paltiel H, Robertson RL. Diagnostic imaging in the evaluation of vascular birthmarks. Dermatol Clin 1998;16(3):455–88. Cross Ref link Pubmed link
  • 142  Dubois J, Garel L, Grignon A, et al. Imaging of hemangiomas and vascular malformations in children. Acad Radiol 1998;5(5):390–400. Cross Ref link Pubmed link
  • 143  Claesson G, Kuylenstierna R. OK‐432 therapy for lymphatic malformation in 32 patients (28 children). Int J Pediatr Otorhinolaryngol 2002;65(1):1–6. Cross Ref link Pubmed link
  • 144  Mathur NN, Rana I, Bothra R, Dhawan R, Kathuria G, Pradhan T. Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol 2005;69(1):75–80. Cross Ref link Pubmed link
  • 145  Alomari AI, Karian VE, Lord DJ, Padua HM, Burrows PE. Percutaneous sclerotherapy for lymphatic malformations: a retrospective analysis of patient‐evaluated improvement. J Vasc Interv Radiol 2006;17(10):1639–48. Cross Ref link Pubmed link
  • 146  Savas JA, Ledon J, Franca K, Chacon A, Zaiac M, Nouri K. Carbon dioxide laser for the treatment of microcystic lymphatic malformations (lymphangioma circumscriptum): a systematic review. Dermatol Surg 2013;39(8):1147–57. Cross Ref link Pubmed link
  • 147  Hammer J, Seront E, Dupont S, et al. Rapamycin as a new treatment option for complex venous and lymphatic anomalies: preliminary results of a single center prospective phase‐II study. (In preparation.)
  • 148  Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. N Eng J Med 2012;366(4):384–6. Cross Ref link
  • 149  Greene AK, Rogers GF, Mulliken JB. Schimmelpenning syndrome: an association with vascular anomalies. Cleft Palate Craniofac J 2007;44(2):208–15. Cross Ref link Pubmed link
  • 150  Groesser L, Herschberger E, Ruetten A, et al. Postzygotic HRAS and KRAS mutations cause nevus sebaceous and Schimmelpenning syndrome. Nat Genet 2012;44(7):783–7. Cross Ref link Pubmed link
  • 151  Irrthum A, Karkkainen MJ, Devriendt K, Alitalo K, Vikkula M. Congenital hereditary lymphedema caused by a mutation that inactivates VEGFR3 tyrosine kinase. Am J Hum Genet 2000;67(2):295–301. Cross Ref link Pubmed link
  • 152  Karkkainen MJ, Ferrell RE, Lawrence EC, et al. Missense mutations interfere with VEGFR‐3 signalling in primary lymphoedema. Nat Genet 2000;25(2):153–9. Cross Ref link Pubmed link
  • 153  Ghalamkarpour A, Holnthoner W, Saharinen P, et al. Recessive primary congenital lymphoedema caused by a VEGFR3 mutation. J Med Genet 2009;46(6):399–404. Cross Ref link Pubmed link
  • 154  Daniel‐Spiegel E, Ghalamkarpour A, Spiegel R, et al. Hydrops fetalis: an unusual prenatal presentation of hereditary congenital lymphedema. Prenat Diagn 2005;25(11):1015–18. Cross Ref link Pubmed link
  • 155  Ghalamkarpour A, Morlot S, Raas‐Rothschild A, et al. Hereditary lymphedema type I associated with VEGFR3 mutation: the first de novo case and atypical presentations. Clin Genet 2006;70(4):330–5. Cross Ref link Pubmed link
  • 156  Brice G, Child AH, Evans A, et al. Milroy disease and the VEGFR‐3 mutation phenotype. J Med Genet 2005;42(2):98–102. Cross Ref link Pubmed link
  • 157  Ghalamkarpour A, Debauche C, Haan E, et al. Sporadic in utero generalized edema caused by mutations in the lymphangiogenic genes VEGFR3 and FOXC2. J Pediatr 2009;155(1):90–3. Cross Ref link Pubmed link
  • 158  Brice G, Mansour S, Bell R, et al. Analysis of the phenotypic abnormalities in lymphoedema‐distichiasis syndrome in 74 patients with FOXC2 mutations or linkage to 16q24. J Med Genet 2002;39(7):478–83. Cross Ref link Pubmed link
  • 159  Ferrell RE, Baty CJ, Kimak MA, et al. GJC2 missense mutations cause human lymphedema. Am J Hum Genet 2010;86(6):943–8. Cross Ref link Pubmed link
  • 160  Ostergaard P, Simpson MA, Brice G, et al. Rapid identification of mutations in GJC2 in primary lymphoedema using whole exome sequencing combined with linkage analysis with delineation of the phenotype. J Med Genet 2011;48(4):251–5. Cross Ref link Pubmed link
  • 161  Gordon K, Schulte D, Brice G, et al. Mutation in vascular endothelial growth factor‐C, a ligand for vascular endothelial growth factor receptor‐3, is associated with autosomal dominant milroy‐like primary lymphedema. Circ Res 2013;112(6):956–60. Cross Ref link Pubmed link
  • 162  Balboa‐Beltran E, Fernandez‐Seara MJ, Perez‐Munuzuri A, et al. A novel stop mutation in the vascular endothelial growth factor‐C gene (VEGFC) results in Milroy‐like disease. J Med Genet 2014;51(7):475–8. Cross Ref link Pubmed link
  • 163  Koshima I, Inagawa K, Urushibara K, Moriguchi T. Supermicrosurgical lymphaticovenular anastomosis for the treatment of lymphedema in the upper extremities. J Reconstr Microsurg 2000;16(6):437–42. Cross Ref link Pubmed link
  • 164  O'Brien BM, Khazanchi RK, Kumar PA, Dvir E, Pederson WC. Liposuction in the treatment of lymphoedema; a preliminary report. Br J Plast Surg 1989;42(5):530–3. Cross Ref link Pubmed link
  • 165  Finegold DN, Kimak MA, Lawrence EC, et al. Truncating mutations in FOXC2 cause multiple lymphedema syndromes. Hum Mol Genet 2001;10(11):1185–9. Cross Ref link Pubmed link
  • 166  Fang J, Dagenais SL, Erickson RP, et al. Mutations in FOXC2 (MFH‐1), a forkhead family transcription factor, are responsible for the hereditary lymphedema‐distichiasis syndrome. Am J Hum Genet 2000;67(6):1382–8. Cross Ref link Pubmed link
  • 167  Petrova TV, Karpanen T, Norrmen C, et al. Defective valves and abnormal mural cell recruitment underlie lymphatic vascular failure in lymphedema distichiasis. Nat Med 2004;10(9):974–81. Cross Ref link Pubmed link
  • 168  Irrthum A, Devriendt K, Chitayat D, et al. Mutations in the transcription factor gene SOX18 underlie recessive and dominant forms of hypotrichosis‐lymphedema‐telangiectasia. Am J Hum Genet 2003;72(6):1470–8. Cross Ref link Pubmed link
  • 169  Moalem S, Brouillard P, Kuypers D, et al. Hypotrichosis‐lymphedema‐telangiectasia‐renal defect associated with a truncating mutation in the SOX18 gene. Clin Genet 2015;87:378–82. Cross Ref link Pubmed link
  • 170  Hennekam RC, Geerdink RA, Hamel BC, et al. Autosomal recessive intestinal lymphangiectasia and lymphedema, with facial anomalies and mental retardation. Am J Med Genet 1989;34(4):593–600. Cross Ref link Pubmed link
  • 171  Alders M, Hogan BM, Gjini E, et al. Mutations in CCBE1 cause generalized lymph vessel dysplasia in humans. Nat Genet 2009;41(12):1272–4. Cross Ref link Pubmed link
  • 172  Alders M, Al‐Gazali L, Cordeiro I, et al. Hennekam syndrome can be caused by FAT4 mutations and be allelic to Van Maldergem syndrome. Hum Genet 2014;133(9):1161–7. Cross Ref link Pubmed link
  • 173  Connell F, Kalidas K, Ostergaard P, et al. Linkage and sequence analysis indicate that CCBE1 is mutated in recessively inherited generalised lymphatic dysplasia. Hum Genet 2010;127(2):231–41. Cross Ref link Pubmed link
  • 174  Jeltsch M, Jha SK, Tvorogov D, et al. CCBE1 enhances lymphangiogenesis via a disintegrin and metalloprotease with thrombospondin motifs‐3‐mediated vascular endothelial growth factor‐C activation. Circulation 2014;129(19):1962–71. Cross Ref link Pubmed link
  • 175  Bellini C, Mazzella M, Arioni C, et al. Hennekam syndrome presenting as nonimmune hydrops fetalis, congenital chylothorax, and congenital pulmonary lymphangiectasia. Am J Med Genet A 2003;120A(1):92–6. Cross Ref link Pubmed link
  • 176  Alfano V, Tritto G, Alfonsi L, Cella A, Pasanisi F, Contaldo F. Stable reversal of pathologic signs of primitive intestinal lymphangiectasia with a hypolipidic, MCT‐enriched diet. Nutrition 2000;16(4):303–4. Cross Ref link Pubmed link
  • 177  Bac DJ, Van Hagen PM, Postema PT, ten Bokum AM, Zondervan PE, van Blankenstein M. Octreotide for protein‐losing enteropathy with intestinal lymphangiectasia. Lancet 1995;345(8965):1639. Cross Ref link Pubmed link
  • 178  Mitsunaga T, Yoshida H, Iwai J, et al. Successful surgical treatment of two cases of congenital chylous ascites. J Pediatr Surg 2001;36(11):1717–19. Cross Ref link Pubmed link
  • 179  Ostergaard P, Simpson MA, Mendola A, et al. Mutations in KIF11 cause autosomal‐dominant microcephaly variably associated with congenital lymphedema and chorioretinopathy. Am J Hum Genet 2012;90(2):356–62. Cross Ref link Pubmed link
  • 180  Au AC, Hernandez PA, Lieber E, et al. Protein tyrosine phosphatase PTPN14 is a regulator of lymphatic function and choanal development in humans. Am J Hum Genet 2010;87(3):436–44. Cross Ref link Pubmed link
  • 181  Kazenwadel J, Secker GA, Liu YJ, et al. Loss‐of‐function germline GATA2 mutations in patients with MDS/AML or MonoMAC syndrome and primary lymphedema reveal a key role for GATA2 in the lymphatic vasculature. Blood 2012;119(5):1283–91. Cross Ref link Pubmed link
  • 182  Emberger JM, Navarro M, Dejean M, Izarn P. [Deaf‐mutism, lymphedema of the lower limbs and hematological abnormalities (acute leukemia, cytopenia) with autosomal dominant transmission.] J Genet Hum 1979;27(3):237–45. Pubmed link